###### Key messages

-   Patients with COPD have a high risk of death when suffering from a myocardial infarction.

-   The increased risk of death seems to partly be based on comorbidities and undertreatment post-MI.

-   By reducing the undertreatment with guideline recommended secondary prevention, their prognosis may be improved.

Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death worldwide but is expected to be the third leading cause in 2030[@R1] in parallel with an expected global increase in tobacco smoking.[@R2] The prevalence of COPD varies between countries and age groups but is estimated to be 9--10% in adults over 40 years of age.[@R3] COPD is an underdiagnosed[@R4] [@R5] and undertreated[@R6] disease with as little as only one-fifth of patients aged over 40 years being diagnosed and treated in a primary care setting.[@R7]

COPD and ischaemic heart disease share common risk factors such as high age and smoking[@R8] and a high portion of morbidity and mortality in patients with COPD is attributable to cardiovascular disease.[@R9]--[@R11] Patients with mild COPD seem to have a higher risk of dying from cardiovascular causes than from respiratory insufficiency.[@R12] Reduced lung function, independent of smoking, has been shown to correlate with a higher risk of cardiovascular death[@R10] [@R13] and ventricular arrhythmia.[@R14] A reduced forced expiratory volume in 1 s (FEV1) has been implicated as a prognostic marker for all-cause and cardiovascular mortality.[@R15] [@R16] Chronic inflammation of the lungs is thought to result in systemic inflammation,[@R17] measured by increased plasma levels of inflammation markers such as C reactive protein (CRP).[@R18] This could possibly aggravate atherosclerosis, induce arterial stiffness[@R19] and contribute to an increased risk of cardiovascular disease.

When suffering from a myocardial infarction (MI), patients with COPD often have comorbidities and commonly present with atypical symptoms, such as dyspnoea, which may result in diagnostic difficulties and delayed treatment leading to a worse prognosis.[@R20] Furthermore, they are less likely to receive reperfusion therapy during hospitalisation[@R21] and other MI therapies of proven benefit.[@R22]

The aim of the present study was to characterise the population with MI with a concurrent COPD diagnosis and investigate the prognostic impact of COPD when suffering from an MI, in a contemporary patient population with widespread use of percutaneous coronary intervention (PCI) and dual antiplatelet inhibition.

Materials and methods {#s2}
=====================

Study sample {#s2a}
------------

Consecutive patients with MI admitted to Swedish coronary care units and entered in the nationwide Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)[@R23] registry between 2005 and 2010 were available for analyses. The study population consisted of a total of 81 191 patients with MI, including ST elevation myocardial infarction (STEMI) and non-STEMI. Of these patients, 4867 (6%) had a previous COPD hospital discharge diagnosis while 76 324 did not. The COPD diagnoses were based on International Classification of Diseases (ICD) codes that can be found in online supplementary table S1.

The SWEDEHEART registry enrols consecutive patients admitted to a coronary care unit because of symptoms suggestive of an acute coronary syndrome. On admission, patients receive written information about SWEDEHEART and other quality-of-care registries; patients are permitted to deny participation in the registry, although few of them exercise this right. According to Swedish law, written consent is not required because quality control is an inherent element of hospital healthcare. Research based on the registry is approved by an institutional ethics committee and all personal identifiers are removed from the SWEDEHEART data file when used for research purposes. Information is collected prospectively regarding baseline characteristics such as age and smoking status as well as ECG findings, examinations, interventions, in-hospital complications, discharge medication and diagnoses.[@R23] Information on time of death was obtained from the Swedish National Cause of Death Registry. Information regarding medical history, including previous COPD diagnoses, and re-admissions for reinfarction, stroke or bleeding was obtained from the Swedish National Patient Registry,[@R24] which includes diagnoses for all patients hospitalised in Sweden from 1987 and forward. Since 2001, the specialised outpatient care is also included. The validity of COPD diagnoses in the Swedish National Patient Registry has recently been reported to be good, with a diagnosis likely to be misclassified in less than 10%.[@R25]

Endpoints {#s2b}
---------

The primary analysis tested the relationship between a prior COPD hospital discharge diagnosis and the primary endpoint of all-cause mortality during 1 year of follow-up after the initial coronary care unit hospitalisation. Secondary endpoints included 1-year re-admission for reinfarction, defined as a new hospitalisation with an MI diagnosis, new-onset admission for stroke, new-onset bleeding and new-onset heart failure. The corresponding ICD codes that the secondary endpoints are based on can be found in online supplementary table S1.

Statistical analyses {#s2c}
--------------------

Rates of predefined endpoints in patients with and without a prior COPD hospital discharge diagnosis were calculated with the Kaplan-Meier estimator. Univariate and multivariate HRs were estimated using the Cox proportional hazards models. Covariates were tested for proportionality by visual inspection. Adjustments for potential confounders were performed stepwise in two models, the first including age, sex, smoking status and comorbidities (previous MI, previous stroke, heart failure, renal failure, hypertension, diabetes, peripheral artery disease, cancer and previous bleeding). The second model also included treatments during hospitalisation and at discharge (heparin, fondaparinux, dalteparin, enoxaparin, GPIIbIIIa-inhibitors, β-blockers, balloon angioplasty, coronary stenting, as well as discharge medications including ACE inhibitors, angiotensin II receptor blockers, aspirin, clopidogrel, prasugrel, β-blockers, calcium channel blockers, digoxin, diuretics, statins, nitrates and warfarin). The selection of covariates included in these models was performed with the use of a direct acyclical graph[@R26] via a web-based tool (<http://www.dagitty.net>), as illustrated in online supplementary figure S1. Differences between continuous variables were evaluated using the Student t test. Differences between categorical variables were analysed with the Pearson χ^2^ test. All tests were two-sided with a p value for significance \<0.05. All analyses were performed in SPSS (SPSS V.20, IBM SPSS statistics).

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

Baseline characteristics for patients with MI and without COPD are outlined in [table 1](#OPENHRT2013000002TB1){ref-type="table"}. Many variables differ between the two groups. The mean age was 5 years higher in patients with COPD as well as a threefold higher prevalence of prior heart failure. Furthermore, there was a more than twice as high proportion of renal failure, peripheral artery disease and cancer in patients with COPD. Patients with COPD were also more likely to have suffered from previous MI and stroke as well as being treated with more cardiovascular medications than the patients with non-COPD at baseline, with the exception of β-blockers.

###### 

Baseline characteristics of 81 191 consecutive patients with MI with and without COPD in Sweden between 2005 and 2010

                                     Non-COPD        COPD          p Value
  ---------------------------------- --------------- ------------- ---------
  Number of patients                 76 324 (94.0)   4867 (6.0)    
  Age                                70±13           75±9          \<0.001
  Female gender                      27 466 (36.0)   2239 (46.0)   \<0.001
  Body mass index (n=55 516)         26.7±4.7        25.4±5.4      \<0.001
  Smoking status (n=80 879)                                        \<0.001
   Current smoker                    16 522 (21.7)   1596 (32.9)   
   Ex--smoker                        20 791 (27.3)   2222 (45.9)   
   Never smoked                      31 850 (41.9)   681 (14.1)    
   Unknown                           6872 (9.0)      345 (7.1)     
  Comorbidities                                                    
   Previous MI                       5990 (7.8)      665 (13.7)    \<0.001
   Previous stroke                   6904 (9.0)      650 (13.4)    \<0.001
   Heart failure                     4836 (6.3)      983 (20.2)    \<0.001
   Renal failure                     1478 (1.9)      231 (4.7)     \<0.001
   Hypertension                      14 848 (19.5)   1537 (31.6)   \<0.001
   Diabetes                          14 613 (19.1)   999 (20.5)    0.018
   Peripheral artery disease         3121 (4.1)      498 (10.2)    \<0.001
   Cancer                            1638 (2.1)      258 (5.3)     \<0.001
   Previous bleeding                 3541 (4.6)      428 (8.8)     \<0.001
   Prior CABG                        2625 (3.4)      208 (4.3)     0.002
   Prior PCI                         1548 (2.0)      127 (2.6)     0.006
  Prior medication before MI                                       
   ACE inhibitor                     12 216 (16.0)   967 (19.9)    \<0.001
   Angiotensin II receptor blocker   7894 (10.5)     580 (12.1)    \<0.001
   Aspirin                           23 023 (30.2)   1913 (39.3)   \<0.001
   Clopidogrel                       2603 (3.4)      217 (4.5)     \<0.001
   β-blocker                         23 315 (30.6)   1544 (31.7)   0.161
   Calcium channel blocker           11 615 (15.2)   878 (18.0)    \<0.001
   Digitalis                         1918 (2.5)      290 (6.0)     \<0.001
   Diuretic                          17 170 (22.5)   1910 (39.2)   \<0.001
   Statin                            14 452 (18.9)   1069 (22.0)   \<0.001
   Nitrate                           6331 (8.3)      630 (12.9)    \<0.001
   Warfarin                          2816 (3.7)      275 (5.7)     \<0.001

The mean and SD are presented for continuous variables and count and percentage for categorical variables.

CABG, coronary arterial bypass graft surgery; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; PCI, percutaneous coronary intervention.

Clinical presentation, laboratory findings and ECG changes {#s3b}
----------------------------------------------------------

The pattern of symptoms differed between the two groups, as shown in [table 2](#OPENHRT2013000002TB2){ref-type="table"}. Patients in the COPD group presented more frequently with dyspnoea and less frequently with chest pain as the main presenting symptom compared to patients without COPD. For the patients with COPD, the mean heart rate was higher, while the lab findings revealed lower mean total cholesterol and low-density lipoprotein levels with a higher mean CRP value. More often, the presenting ECG showed atrial fibrillation or flutter in the COPD group and the QRS complex revealed higher percentages of left bundle branch block and right bundle branch block. In contrast, ST elevation was more frequent in the non-COPD group.

###### 

Characteristics at presentation for 81 191 consecutive patients with MI with and without COPD in Sweden between 2005 and 2010

                                  Non-COPD        COPD          p Value
  ------------------------------- --------------- ------------- ---------
  Number of patients              76 324 (94.0)   4867 (6.0)    
  Presenting symptoms                                           \<0.001
   Chest pain                     63 143 (82.9)   3191 (65.6)   
   Dyspnoea                       5429 (7.1)      1092 (22.5)   
   Cardiac arrest                 836 (1.1)       45 (0.9)      
   Other                          6343 (8.3)      505 (10.4)    
  Delays from symptom onset                                     
   Symptom onset to ER \<12 h     41 897 (88.7)   2461 (87.6)   0.092
   Symptom onset to ICCU \<12 h   60 084 (87.4)   3508 (84.0)   \<0.001
   Symptom onset to PCI \<12 h    17 623 (91.9)   690 (91.1)    0.488
  Clinical findings                                             
   Pulmonary oedema               1542 (2.1)      140 (3.0)     \<0.001
   Heart rate                     80±23           90±25         \<0.001
   Systolic blood pressure        147±30          141±30        \<0.001
   Diastolic blood pressure       84±17           80±18         \<0.001
  Lab findings                                                  
   Total cholesterol              5.1±1.2         4.8±1.2       \<0.001
   LDL                            3.1±1.1         2.8±1.0       \<0.001
   HDL                            1.2±0.4         1.3±0.5       \<0.001
   Creatinine                     95±57           100±60        0.001
   CRP                            25±50           38±60         \<0.001
   Hb                             138±18          134±18        \<0.001
  Presenting ECG                                                
   Rhythm                                                       \<0.001
    Sinus                         66 131 (86.7)   3958 (81.4)   
    Atrial fibrillation/flutter   7686 (10.1)     706 (14.5)    
   QRS                                                          \<0.001
    Normal                        47 474 (62.7)   2711 (56.1)   
    LBBB                          4329 (5.7)      397 (8.2)     
    RBBB                          3231 (4.3)      300 (6.2)     
   ST-T segment                                                 \<0.001
    Normal                        14 595 (19.2)   941 (19.4)    
    ST elevation                  27 012 (35.5)   1294 (26.7)   
    ST depression                 16 717 (22.0)   1205 (24.8)   
    Abnormal T wave               7681 (10.1)     528 (10.9)    
    Other                         9056 (11.9)     791 (16.3)    

The mean and SD are presented for continuous variables and count and percentage for categorical variables.

COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; ER, emergency room; Hb, haemoglobin; HDL, high-density lipoprotein; ICCU, intensive coronary-care unit; LDL, low-density lipoprotein; LBBB, left bundle branch block; PCI, percutaneous coronary intervention; RBBB, right bundle branch block.

Treatments, angiographic findings, complications during hospitalisation and discharge medications {#s3c}
-------------------------------------------------------------------------------------------------

The in-hospital characteristics for patients with MI with and without COPD are outlined in [table 3](#OPENHRT2013000002TB3){ref-type="table"}. Invasive investigation and treatments in the form of coronary angiography, balloon angioplasty and stenting were less frequent among patients with COPD while the rate of coronary arterial bypass graft surgery did not differ. The indications for PCI differed between the groups, with STEMI being more prevalent among patients in the non-COPD group while the extent of coronary disease was similar.

###### 

In-hospital characteristics of 81 191 consecutive patients with MI with and without COPD in Sweden between 2005 and 2010

                                          Non-COPD        COPD          p Value
  --------------------------------------- --------------- ------------- ---------
  Number of patients                      76 324 (94.0)   4867 (6.0)    
  Prehospital thrombolysis                946 (1.4)       34 (0.8)      0.007
  Anticoagulant therapy                                                 \<0.001
   Heparin                                5413 (7.1)      198 (4.1)     
   Dalteparin/enoxaparin                  34 266 (44.9)   2311 (47.5)   
   Fondaparinux                           15 705 (20.6)   1147 (23.6)   
  GPIIBIIIA-inhibition                                                  \<0.001
   Abciximab                              12 342 (16.2)   434 (8.9)     
   Tirofiban                              1464 (1.9)      48 (1.0)      
   Eptifibatide                           4078 (5.3)      145 (3.0)     
  β-blocker                                                             \<0.001
   Intravenous                            17 746 (23.3)   908 (18.7)    
   Oral                                   35 500 (46.5)   2072 (42.6)   
  Coronary angiography                    55 330 (72.5)   2697 (55.4)   \<0.001
  Indication for angiography                                            \<0.001
   Unstable angina/NSTEMI                 30 015 (54.2)   1610 (59.9)   
   STEMI                                  21 136 (38.2)   883 (32.9)    
   Other                                  4251 (7.6)      194 (7.2)     
  Angiographic findings                                                 \<0.001
   Normal/atheromatosis                   760 (1.7)       47 (2.4)      
   1-vessel, no left main disease         20 788 (47.3)   860 (43.8)    
   2-vessel, no left main disease         13 038 (29.7)   575 (29.3)    
   3-vessel, no left main disease         7534 (17.1)     367 (18.7)    
   Left main disease                      226 (0.5)       14 (0.7)      
  PCI                                     42 540 (55.7)   1837 (37.7)   \<0.001
  Stented                                 40 662 (53.3)   1746 (35.9)   \<0.001
  CABG                                    2211 (2.9)      120 (2.5)     0.081
  Complications                                                         
   Prehospital CPR                        1129 (1.6)      48 (1.2)      0.040
   Cardiogenic shock                      1990 (2.7)      135 (2.8)     0.717
   Defibrillated VT/VF                    1903 (2.5)      110 (2.3)     0.285
   Rupture                                107 (0.1)       6 (0.1)       0.097
   Reinfarction during hospital stay      956 (1.3)       67 (1.4)      0.422
   CPAP usage                             3700 (4.8)      477 (9.8)     \<0.001
   Bleeding causing surgery/transfusion   1233 (1.6)      117 (2.4)     0.001
   AV block II/III                        1424 (1.9)      94 (1.9)      0.160
   Permanent pacemaker                    735 (1.0)       52 (1.1)      0.344
   New onset atrial fibrillation          3462 (4.6)      249 (5.2)     0.107
   Discharged with flutter/fibrillation   4519 (6.3)      417 (9.3)     \<0.001
  LVEF at discharge                                                     \<0.001
   Normal LVEF ≥50%                       28 988 (53.8)   1422 (45.0)   
   LVEF 40--49%                           12 338 (22.9)   770 (24.3)    
   LVEF 30--39%                           7748 (14.4)     545 (17.2)    
   LVEF \<30%                             3809 (7.1)      342 (10.8)    
  Discharge medications                                                 
   ACE inhibitor                          42 350 (55.5)   2460 (50.6)   \<0.001
   Angiotensin II blocker                 8276 (11.1)     602 (12.6)    0.001
   Aspirin                                68 693 (90.1)   4158 (85.5)   \<0.001
   Other platelet inhibitor                                             \<0.001
    Clopidogrel                           54 439 (71.4)   3003 (61.8)   
    Prasugrel                             331 (0.4)       9 (0.2)       
    Other                                 341 (0.4)       23 (0.5)      
   β-blocker                              65 675 (86.1)   3778 (77.7)   \<0.001
   Statin                                 60 387 (79.2)   3323 (68.4)   \<0.001
   Calcium channel blocker                 9530 (12.5)    735 (15.1)    \<0.001
   Digoxin                                2309 (3.0)      294 (6.0)     \<0.001
   Diuretic                               22 910 (30.0)   2397 (49.3)   \<0.001
   Nitrate                                9736 (12.8)     878 (18.1)    \<0.001
   Warfarin                               4039 (5.3)      314 (6.5)     0.008

The count and percentage are presented for all categorical variables.

AV, atrioventricular; CABG, coronary arterial bypass graft surgery; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; CPR, cardiopulmonary resuscitation; LVEF, left ventricular ejection fraction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; VF, ventricular fibrillation; VT, ventricular tachycardia.

Continuous positive airway pressure usage was more common for the COPD group as well as a bleeding requiring transfusion and/or surgery. Patients in the COPD group were also more likely to be discharged with atrial flutter or atrial fibrillation as well as with a lower left ventricular ejection fraction.

Patients with COPD were discharged with fewer medications that have been proven to reduce mortality such as aspirin and other platelet inhibitors as well as β-blockers, statins and ACE inhibitors but more of angiotensin receptor blockers. In contrast, patients in the COPD group were more often discharged with calcium channel blockers, digoxin, diuretics, nitrates and warfarin.

Outcomes {#s3d}
--------

The crude 1-year mortality was significantly higher in the COPD group compared to the non-COPD group, 24.6% vs 13.8% (HR 1.86, 95% CI 1.76 to 1.98), as shown in [figure 1](#OPENHRT2013000002F1){ref-type="fig"} and [table 4](#OPENHRT2013000002TB4){ref-type="table"}. After adjusting for differences in baseline characteristics, the mortality remained higher in the COPD group but the HR was significantly lowered (HR 1.32, 95% CI 1.24 to 1.40). After additional adjustment for treatments during hospitalisation and discharge medications, the difference in mortality was further decreased but remained statistically significant (HR 1.14, 95% CI 1.07 to 1.21).

###### 

Clinical endpoints for patients with COPD as compared to patients without COPD at 1 year

                            Crude HR (95% CI)           Adjusted† HR (95% CI)       Adjusted‡ HR (95% CI)
  ------------------------- --------------------------- --------------------------- ---------------------------
  All-cause mortality       1.86 (1.76 to 1.98)\*\*\*   1.32 (1.24 to 1.40)\*\*\*   1.14 (1.07 to 1.21)\*\*\*
  Reinfarction              1.17 (1.09 to 1.26)\*\*\*   1.00 (0.93 to 1.08)         0.99 (0.92 to 1.06)
  New-onset stroke          1.14 (0.93 to 1.40)         0.90 (0.73 to 1.12)         0.89 (0.72 to 1.11)
  New-onset bleeding        1.45 (1.25 to 1.69)\*\*\*   1.13 (0.96 to 1.32)         1.12 (0.96 to 1.31)
  New-onset heart failure   1.84 (1.70 to 1.99)\*\*\*   1.46 (1.34 to 1.58)\*\*\*   1.35 (1.24 to 1.47)\*\*\*

\*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.

†Adjustment for age, gender, smoking and comorbidity.

‡Adjustment for age, gender, smoking, comorbidity, treatment during hospitalisation and discharge medications.

COPD, chronic obstructive pulmonary disease.

![A Kaplan-Meier plot showing the crude 1-year mortality for patients with chronic obstructive pulmonary disease (COPD) versus patients without COPD.](openhrt2013000002f01){#OPENHRT2013000002F1}

The results of the secondary endpoint analyses are shown in [table 4](#OPENHRT2013000002TB4){ref-type="table"}. Patients with COPD had a higher rate of reinfarction 16.6% vs 14.2% (HR 1.17, 95% CI 1.09 to 1.26), new-onset bleeding 4.1% vs 2.8% (HR 1.45, 95% CI 1.25 to 1.69) and new-onset heart failure 17.2% vs 9.7% (HR 1.84, 95% CI 1.70 to 1.99) compared to the non-COPD group in univariate analyses, while there was no difference in the rate of new-onset strokes. However, after adjusting for differences in baseline characteristics, treatment during hospitalisation and discharge medications, no differences in reinfarction rates or new-onset bleeding rates were noted. In contrast, the rate of new-onset heart failure remained higher for patients with COPD (HR 1.35, 95% CI 1.24 to 1.47).

Discussion {#s4}
==========

Currently, there is limited knowledge about the effect of concomitant COPD on patients with MI regarding mortality and other cardiovascular events, especially in patients with contemporary treatment including PCI, dual antiplatelet therapy and statins. Our nationwide and contemporary study has a large patient population and reflects the present MI care in Sweden well. Thus, it provides new information to the field of patients with MI with a concurrent COPD diagnosis.

Patient characteristics {#s4a}
-----------------------

In our study, 6% of the study population had a COPD hospital discharge diagnosis, lower than the estimated prevalence of COPD in the general population (9--10%), a finding in accordance with the previously reported problems of underdiagnosis.[@R3] The increased age in the COPD group probably reflects that COPD is a late effect of lifelong smoking, but it could also be explained by underdiagnosis since COPD is relatively silent in early stages, and therefore the diagnosis does not surface until the manifestations are severe. As [table 1](#OPENHRT2013000002TB1){ref-type="table"} outlines, many of these patients also have previous cardiovascular events, in part due to a heavy smoking history but perhaps also due to reduced lung function and chronic inflammation of the lungs.

With regard to baseline characteristics and clinical presentation, several findings in our study are supported by previous studies. We found that patients with COPD had a larger burden of comorbidity and more atypical MI symptoms at presentation, in accordance with the findings of a previous study.[@R20] However, we did not observe any differences in time delays from symptom onset to PCI or to the emergency room, as previously reported.[@R20] Our data also did not support a previous study showing higher rates of cardiogenic shock in patients with COPD.[@R27]

Treatments {#s4b}
----------

After an MI, many patients with COPD have previously not been prescribed β-blockers[@R28] because clinicians fear that β-blockers will provoke bronchospasm and induce respiratory failure, even though cardioselective β-blockers have been proven to be safe and should not be routinely withheld from patients with COPD.[@R29] Other types of standard post-MI treatment such as aspirin may also be used less often.[@R22]

As [table 3](#OPENHRT2013000002TB3){ref-type="table"} outlines, our findings are in line with these previous studies and show that standard post-MI treatment is withheld from patients with COPD more often than patients without COPD, especially with respect to β-blockers and surprisingly also statins which previously in observational studies have shown a dual cardiopulmonary protective effect.[@R30] A systematic review including nine previous studies suggests that statins may also have a beneficial role in the treatment of COPD in itself.[@R31]

Outcomes {#s4c}
--------

Previous studies have reported conflicting findings. Bursi *et al*[@R21] reported a worse 5-year survival rate in patients with COPD (46%) compared to those without COPD (68%), and the association between COPD and death was independent of age and risk factors (HR 1.30, 95% CI 1.10 to 1.54). In another study by Salisbury *et al*[@R22], patients with COPD had a twofold higher 1-year mortality rate after adjustment for baseline differences (HR 2.00, 95% CI 1.44 to 2.79) and higher rehospitalisation rates (HR 1.22, 95% CI 1.01 to 1.48). On the other hand, the older study by Behar *et al*[@R32] did not find an independent association between COPD and a higher risk of early death or long-term mortality among survivors of acute MI.

Our study showed that patients with a prior COPD hospital discharge diagnosis had a considerably higher crude 1-year mortality after an MI (HR 1.86, 95% CI 1.76 to 1.98) compared to patients without COPD with an MI. However, we could show that this association was greatly lowered after adjusting for baseline characteristics and comorbidities (HR 1.32, 95% CI 1.24 to 1.40) and, perhaps most importantly, after also adjusting for different treatment patterns, only a modest increase in adjusted mortality remained (HR 1.14, 95% CI 1.07 to 1.21).

Therefore, our results indicate that patients with COPD with an MI constitute a very high risk group with a nearly doubled unadjusted mortality rate compared to patients without COPD with an MI and that the excess mortality could perhaps be lowered with more aggressive evidence-based treatments for both the MI as well as concomitant diseases. However, our results are only suggestive and it would require a prospective, interventional study to confirm our findings. COPD was not independently associated with a higher 1-year re-admission for reinfarction, new-onset stroke or new-onset bleeding rate but was independently associated with an increased new-onset heart failure rate.

The observed association between a prior COPD diagnosis before MI and a higher frequency of subsequent new onset of heart failure even after multivariate adjustment raises several questions. Not much is known about the association of heart failure and COPD. Previous authors have suggested a common inflammatory background between the conditions.[@R33] The actual prevalence of decreased left ventricular function in patients with COPD is largely unknown and clinically poorly defined.[@R33] [@R34] Shared signs, symptoms and pulmonary function test findings between heart failure and COPD further complicate the relationship. Patients with COPD may suffer from pulmonary hypertension,[@R35] which could lead to right ventricular dysfunction,[@R36] and because of a similar symptomatology between cor pulmonale and true left ventricular failure, it is hard to discern and distinguish the exact aetiology of the heart failure diagnosis. Dyspnoea and exercise intolerance are cardinal symptoms for COPD and heart failure resulting in diagnostic difficulties, and misclassification in the National Patient Registry cannot be ruled out. However, in the present study, patients with COPD did have a higher rate of decreased left ventricular ejection fraction at discharge and they were also undertreated post-MI with guideline recommended secondary prevention medications. This could lead to a higher frequency of new-onset heart failure.

Limitations {#s4d}
-----------

Our study design was observational, and thus a certain degree of residual confounding cannot be ruled out. Since COPD is an underdiagnosed disease,[@R4] [@R5] a number of patients in the non-COPD group could have met the criteria for COPD if they had been thoroughly investigated with spirometry, an inherent limitation of any retrospective COPD study.[@R37] The underdiagnosis of COPD could potentially result in an under-representation in the registry that could underestimate our findings. Furthermore, we did not have optimal data regarding the patients' smoking history, as pack-years, date of smoking cessation and information about smoking post-MI were lacking. We also did not have information on pulmonary function testing, such as FEV1/forced vital capacity ratios, and therefore the severity of COPD diagnoses cannot be evaluated in our patient population. Moreover, a wide range of physicians has diagnosed the COPD cases, and thus the criteria for COPD may differ between patients in the population. The same problem is applicable to the heart failure diagnoses. However, the validity of COPD and heart failure diagnoses in national Swedish registers has recently been reported to be good.[@R25] [@R38]

Conclusions {#s5}
===========

The main finding in this nationwide study of patients with MI with contemporary treatment including dual antiplatelet treatment and PCI was that a COPD diagnosis at baseline was associated with a high 1-year mortality. However, after multivariate adjustment for comorbidities and different treatment patterns, the residual increase in mortality was only modest (HR 1.14, 95% CI 1.07 to 1.21). There was also an independent association between a COPD diagnosis and re-admission for new-onset heart failure. The mechanisms behind these associations are not clear. However, our findings suggest that improved cardiac treatment in patients with MI with COPD according to current guidelines could potentially result in improved survival.
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